Continuous disclosure rules were no friend to MSB in December when they were forced to advise the market that the primary end point had been missed. It was obvious from that announcement that the underlying data (secondary end points) showed significant benefits, but the market sold the headline.
Fortunately we now have the rest of the information which was not available in December, and wow what a story it tells. I'm very keen to see how this is received in the US tonight as they will have had some time to digest this before open. I suggest it will be far more significant than the +12% we are sitting at here.
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-94
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |